Sedative, Hypnotic, or Anxiolytic Use Disorder

Clinical picture

• Dose escalation, early refill requests, and multiple prescribers, typically beginning with legitimate treatment of anxiety or insomnia.
• Intoxication resembles alcohol with slurred speech, ataxia, nystagmus, disinhibition, and anterograde amnesia, but without any odor.
• Interdose withdrawal on short-acting agents such as alprazolam produces rebound anxiety that patients interpret as worsening illness.
• Withdrawal includes tremor, insomnia, autonomic hyperactivity, perceptual distortion, and seizures, and can be fatal if stopped abruptly.
• Older adults present with falls, hip fractures, confusion, and apparent cognitive decline that partially reverses after a careful taper.
• Co-use with opioids or alcohol is common and multiplies respiratory depression, sedation, and overall overdose mortality risk.

Criteria snapshot

• Requires at least 2 of 11 criteria within a 12-month period, with severity graded mild 2-3, moderate 4-5, or severe 6 or more.
• Tolerance and withdrawal are excluded from the count when the medication is taken as prescribed under appropriate medical supervision.
• Physiologic dependence alone in a properly monitored patient does not establish the diagnosis, since impaired control must also be present.
• Sedative withdrawal is a separate diagnosis requiring 2 or more characteristic symptoms within hours to days of cessation or dose reduction.
• The class spans benzodiazepines, Z-drugs, barbiturates, carbamates, and most prescription sleep and anxiolytic medications.

Neurobiology

• Benzodiazepines act as positive allosteric modulators at GABA-A receptors, increasing the frequency of chloride channel opening.
• Z-drugs such as zolpidem bind preferentially to alpha1-containing subunits, favoring sedation and amnesia over anxiolysis.
• Chronic exposure downregulates GABA-A receptors and upregulates glutamatergic tone, producing rebound hyperexcitability on cessation.
• Barbiturates directly open the chloride channel, which explains their far narrower therapeutic index and their lethality in overdose.
• Kindling from repeated withdrawal episodes escalates seizure risk over time, closely mirroring the pattern observed with alcohol.
• Long-term use is associated with impaired attention, visuospatial ability, and psychomotor speed, with partial recovery after cessation.

Psychology

• Rapid symptom relief teaches immediate avoidance of anxiety, blocking the extinction learning that exposure-based therapy depends on.
• Patients attribute all symptom relief to the medication and develop low self-efficacy for tolerating anxiety without taking it.
• Fear of withdrawal, rather than craving for euphoria, is usually the central obstacle to starting and completing a taper.
• Iatrogenic origin creates an alliance problem, since patients often feel blamed for a dependence that a clinician initiated.
• Catastrophic interpretation of ordinary bodily sensations during taper drives dose reinstatement, and cognitive work reduces this risk.

Differential & comorbidity

• Differentiate from primary anxiety, panic, and insomnia disorders that were never adequately treated with first-line therapies.
• Rule out alcohol use disorder, which shares cross-tolerance with sedatives and requires simultaneous management during withdrawal.
• Comorbid opioid use disorder is common and raises fatal overdose risk, prompting the FDA boxed warning update issued in 2020.
• Screen for depression, PTSD, and personality pathology, all of which predict taper difficulty, dropout, and later reinstatement.
• In older adults evaluate falls, delirium, and driving safety, since benzodiazepines appear on the Beers Criteria avoid list.

Pharmacologic treatment

• Convert to a long-acting agent such as diazepam or clonazepam, then taper roughly 5% to 10% of the dose every 2 to 4 weeks.
• Slow the taper markedly near the end and let the patient help set the pace, since abrupt discontinuation risks seizures and delirium.
• Flumazenil is contraindicated in chronic users because reversal can precipitate refractory seizures in the overdose setting.
• Adjuncts with some support include gabapentin, pregabalin, and melatonin for taper-related insomnia and anxiety.
• Treat the underlying disorder concurrently with an SSRI or SNRI, allowing 4 to 8 weeks for the full therapeutic effect.

Psychotherapy

• CBT delivered during the taper roughly doubles successful discontinuation compared with taper alone at 12-month follow-up.
• CBT-I should replace hypnotic medication as first-line insomnia treatment either before or alongside the taper itself.
• Interoceptive exposure and panic-focused CBT rebuild tolerance for the very sensations the medication had been suppressing.
• Motivational interviewing addresses ambivalence when a patient is satisfied with a medication the clinician wants discontinued.
• Personalized written taper letters from prescribers, as tested in the EMPOWER trial, produce discontinuation without therapy contact.

Adjunct options

• Set a collaborative and flexible taper schedule in writing, since unilateral or forced tapers drive illicit acquisition and harm.
• Prescribe naloxone whenever opioids are co-prescribed, and consolidate prescribing to a single clinician and single pharmacy.
• Address sleep hygiene, exercise, and caffeine intake, and warn patients that rebound insomnia peaks in the first one to two weeks.
• Use ASAM criteria: inpatient withdrawal management is indicated for high doses, seizure history, or significant polysubstance use.
• Monitor with prescription drug monitoring programs, urine testing, and validated anxiety and sleep outcome measures over time.

Clinical pearls

• Sedative withdrawal, like alcohol withdrawal, can kill; never stop it abruptly.
• Flumazenil is contraindicated in chronic users; it precipitates seizures.
• Taper about 5% to 10% every 2 to 4 weeks and slow further near the end.